title: Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.
abstract: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, frequently metastatic sarcomas that are associated with neurofibromatosis type 1 (NF1), a prominent inherited genetic disease in humans. Although loss of the NF1 gene predisposes to MPNST induction, relatively long tumor latency in NF1 patients suggests that additional genetic or epigenetic abnormalities are needed for the development of these nerve sheath malignancies. To study the molecular pathways contributing to the formation of MPNSTs in NF1 patients, we used a zebrafish tumor model defined by nf1 loss in a p53-deficient background together with the overexpression of either wild-type or constitutively activated PDGFRA (platelet-derived growth factor receptor-α) under control of the sox10 neural crest-specific promoter. Here we demonstrate the accelerated onset and increased penetrance of MPNST formation in fish overexpressing both the wild-type and the mutant PDGFRA transgenes in cells of neural crest origin. Interestingly, overexpression of the wild-type PDGFRA was even more potent in promoting transformation than the mutant PDGFRA, which is important because ~78% of human MPNSTs have expression of wild-type PDGFRA, whereas only 5% harbor activating mutations of the gene encoding this receptor. Further analysis revealed the induction of cellular senescence in zebrafish embryos overexpressing mutant, but not wild-type, PDGFRA, suggesting a mechanism through which the oncogenic activity of the mutant receptor is tempered by the activation of premature cellular senescence in an NF1-deficient background. Taken together, our study suggests a model in which overexpression of wild-type PDGFRA associated with NF1 deficiency leads to aberrant activation of downstream RAS signaling and thus contributes importantly to MPNST development-a prediction supported by the ability of the kinase inhibitor sunitinib alone and in combination with the MEK inhibitor trametinib to retard MPNST progression in transgenic fish overexpressing the wild-type receptor.
authors.affiliation: Department of Pediatric Oncology, Harvard Medical School/Dana-Farber Cancer Institute, Children's Hospital Boston, Boston, MA, USA.
authors.forename: D H
authors.initials: DH
authors.lastname: Ki
authors.affiliation: Department of Pediatric Oncology, Harvard Medical School/Dana-Farber Cancer Institute, Children's Hospital Boston, Boston, MA, USA.
authors.forename: S
authors.initials: S
authors.lastname: He
authors.affiliation: Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Rodig
authors.affiliation: Department of Pediatric Oncology, Harvard Medical School/Dana-Farber Cancer Institute, Children's Hospital Boston, Boston, MA, USA.
authors.forename: A T
authors.initials: AT
authors.lastname: Look
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D004625:Embryo, Nonmammalian / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D009442:Neurilemmoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D025542:Neurofibromin 1 / Q000235:genetics / Q000378:metabolism*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D015027:Zebrafish / Q000196:embryology* / Q000235:genetics
chemical_list: D025542:Neurofibromin 1; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D020796:Receptor, Platelet-Derived Growth Factor alpha